Net Income

Most hospitals have static defenses ill-equipped for modern threats. A new, free framework offers a clinically-informed path to a dynamic Zero Trust posture.

With its stock under pressure, Geron will face investors to defend its RYTELO sales strategy and address delays in its pivotal myelofibrosis trial.

America's power grid is at a breaking point. A new report reveals how homeowners and smart tech are forging a resilient, decentralized energy future.

Amid financial headwinds, CISO Global appoints a new EVP to accelerate AI innovation, enhance operational efficiency, and gain a competitive edge.

Outdoor Holding Co. ends a major legal distraction with a $4.4M payment, allowing it to fully focus on innovating its GunBroker.com marketplace.

Humane Colorado and San Francisco SPCA partner with RKD Group, signaling a major shift to data-driven strategies to boost donations and save more lives.

BioVie faces a pivotal moment, touting breakthrough drugs for Alzheimer's and cirrhosis while navigating clinical setbacks and financial pressures.

At a key industry summit, Sutro Biopharma showcases its next-gen ADC platform, designed to overcome treatment resistance with "supercharged" dual-payload drugs.

As Lyell presents at three major investor conferences, the biotech's pipeline, financial health, and future in cancer therapy are under scrutiny.

A Malaysian biotech's new study shows its NK cell therapy is safe, using a novel, low-cost method that could make advanced cancer treatment affordable worldwide.

OptimumBank Holdings leverages its deep expertise in healthcare and multifamily real estate by launching OptimumFunding, a new HUD and FHA lending platform.

Facing financial headwinds, network supplier DAVOLINK is merging with LoadRunner, pivoting to the booming but brutal AI-driven industrial automation market.

As cardiovascular disease affects nearly half of US adults, experts are urging a shift to existing, life-saving therapies that are widely ignored.

Verrica Pharmaceuticals heads to a key investor conference with strong YCANTH sales, a promising pipeline for warts and skin cancer, and high expectations.

With a novel skin drug launched, Pelthos Therapeutics heads to a key conference. Can its focused strategy convince Wall Street of its blockbuster potential?

ITF Therapeutics will unveil 10 new data presentations on its Duchenne therapy, DUVYZAT, offering critical new insights on long-term safety and efficacy.

Roots names Rosie Pouzar as Chief Commercial Officer, leveraging her Sephora and omnichannel expertise to accelerate growth and redefine the brand's future.

With key investor conferences looming, Phathom Pharmaceuticals is set to showcase strong VOQUEZNA sales and a clear path to 2026 profitability.

After halting all R&D, PCI Biotech proposes dissolution and delisting, marking the end for its novel drug delivery platform and a warning for investors.

Pure Storage rebrands as Everpure and acquires 1touch, betting its future on providing the intelligent data management layer essential for enterprise AI.